BrightGene Bio Medical Technology C (SHG:688166) — Market Cap & Net Worth
Market Cap & Net Worth: BrightGene Bio Medical Technology C (688166)
BrightGene Bio Medical Technology C (SHG:688166) has a market capitalization of $2.68 Billion (CN¥18.28 Billion) as of June 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #5372 globally and #1033 in its home market, demonstrating a 0.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BrightGene Bio Medical Technology C's stock price CN¥43.21 by its total outstanding shares 423103851 (423.10 Million). Review total liabilities of BrightGene Bio Medical Technology C to assess the company's total debt and financial obligations.
BrightGene Bio Medical Technology C Market Cap History: 2019 to 2026
BrightGene Bio Medical Technology C's market capitalization history from 2019 to 2026. Data shows growth from $1.94 Billion to $2.68 Billion (5.58% CAGR).
BrightGene Bio Medical Technology C Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BrightGene Bio Medical Technology C's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.46x
BrightGene Bio Medical Technology C's market cap is 1.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.88x
BrightGene Bio Medical Technology C's market cap is 9.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.94 Billion | $503.16 Million | $111.08 Million | 3.85x | 17.45x |
| 2020 | $2.80 Billion | $785.38 Million | $169.88 Million | 3.56x | 16.48x |
| 2021 | $2.25 Billion | $1.05 Billion | $243.95 Million | 2.14x | 9.22x |
| 2022 | $1.39 Billion | $1.02 Billion | $239.62 Million | 1.37x | 5.80x |
| 2023 | $2.17 Billion | $1.18 Billion | $202.47 Million | 1.84x | 10.70x |
| 2024 | $1.87 Billion | $1.28 Billion | $189.17 Million | 1.46x | 9.88x |
Competitor Companies of 688166 by Market Capitalization
Companies near BrightGene Bio Medical Technology C in the global market cap rankings as of June 22, 2026.
Key companies related to BrightGene Bio Medical Technology C by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
BrightGene Bio Medical Technology C Historical Marketcap From 2019 to 2026
Between 2019 and today, BrightGene Bio Medical Technology C's market cap moved from $1.94 Billion to $ 2.68 Billion, with a yearly change of 5.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.68 Billion | -11.92% |
| 2025 | CN¥3.04 Billion | +62.45% |
| 2024 | CN¥1.87 Billion | -13.71% |
| 2023 | CN¥2.17 Billion | +55.88% |
| 2022 | CN¥1.39 Billion | -38.18% |
| 2021 | CN¥2.25 Billion | -19.66% |
| 2020 | CN¥2.80 Billion | +44.39% |
| 2019 | CN¥1.94 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of BrightGene Bio Medical Technology C was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.68 Billion USD |
| MoneyControl | $2.68 Billion USD |
| MarketWatch | $2.68 Billion USD |
| marketcap.company | $2.68 Billion USD |
| Reuters | $2.68 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more